



August 8, 2016

GlycoMimetics to Present at Canaccord Genuity 36th Annual Growth Conference

ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at Canaccord Genuity 36th Annual Growth Conference in Boston, on Thursday, August 11, 2016 2:30 p.m. ET.

To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at www.glycomimetics.com.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell disease. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML. GlycoMimetics expects to initiate trials of its third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist, in the second half of 2016. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160808005484/en/>

GlycoMimetics, Inc.

Investor Contact:

Shari Annes, 650-888-0902

sannes@annesassociates.com

or

Media Contact:

Jamie Lacey-Moreira, 410-299-3310

jamielacey@presscommpr.com

Source: GlycoMimetics, Inc.

News Provided by Acquire Media